nach oben

Rheumatology International

Erschienen in:

01.12.2011 | Review

Cytokine modulators in the treatment of sarcoidosis

verfasst von: E. Bargagli, C. Olivieri, P. Rottoli

Erschienen in: Rheumatology International | Ausgabe 12/2011

Einloggen, um Zugang zu erhalten

Abstract

Sarcoidosis is a granulomatous lung disease in which several cytokines play a pivotal pathogenetic role. Steroid-resistant disease can be treated with immunosuppressive drugs, antimalarial therapies and recently with anti-TNFα agents. The use of biological agents for the treatment of sarcoidosis springs from research into the pathogenesis of the disease and also from the experience of rheumatologists with other chronic inflammatory diseases. Rituximab, golimumab and ustekinumab are cytokine modulators, useful in the treatment of immunoinflammatory disorders, for which randomized trials to evaluate safety and efficacy in sarcoidosis are not yet available. Novel anticytokine drugs administered alone or in association may offer a new approach to treatment of the disease. This review focuses on recent advances in anti-TNFα agents and cytokine modulators for the treatment of sarcoidosis and their therapeutic prospects.

Hunninghake GW, Costabel U, Ando M et al (1999) ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 16:149–173PubMed

Bradley B, Branley HM, Egan JJ et al (2008) Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 63:1–58CrossRef

King CS, Kelly W (2009) Treatment of sarcoidosis. Dis Mon 55:704–718PubMedCrossRef

Baughman RP, Costabel U, Du Bois RM (2008) Treatment of sarcoidosis. Clin Chest Med 29:533–548PubMedCrossRef

Baughman RP, Lower EE (2005) Therapy for sarcoidosis. Eur Respir Mon 32:301–315CrossRef

Sweiss NJ, Curran j, Baughman RP (2007) Sarcoidosis, role of TNF inhibitors and other biological agents: past, present and future concepts. Clin Dermatol 25:341–346PubMedCrossRef

Muller-Quernheim J (1998) Sarcoidosis: immunopathogenetic concepts and their clinical application. Eur Respir J 12:716–738PubMedCrossRef

Fehrenbach H, Zissel G, Goldman T et al (2003) Alveolar macrophages are the main source for tumour necrosis factor-α in patients with sarcoidosis. Eur Respir J 21:421–428PubMedCrossRef

Baughman RP, Stohofer SA, Buchsbaum J, Lower EE (1990) Release of TNF by alveolar macrophages of patients with sarcoidosis. J Lab Clin Med 115:36–42PubMed

10.

Ziegenhagen MW, Rothe E, Zissel G, Muller Quernheim J (2002) Exaggerated TNF alpha release of alveolar macrophages in corticosteroid resistant sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 19:185–190PubMed

11.

Ziegenhagen MW, Benner UK, Zissel G, Zabel P, Schlaak M, Muller Quernheim J (1997) Sarcoidosis: TNF α release from alveolar macrophages and serum levels of sIL-2R are prognostic markers. Am J Respir Crit Care Med 156:1586–1592PubMed

12.

Bargagli E, Mazzi A, Rottoli P (2008) Markers of inflammation in sarcoidosis: blood, urine, BAL, sputum and exhaled gas. Clin Chest Med 29:445–458PubMedCrossRef

13.

Sinigallia F (2000) IL-12 in lung diseases. Sarcoidosis Vasc Diffuse Lung Dis 17:122–124

14.

Shigehara K, Shijubo N, Ohmichi M et al (2003) Increased circulating interleukin-12 (IL-12) p40 in pulmonary sarcoidosis. Clin Exp Immunol 132:152–157PubMedCrossRef

15.

Shigehara K, Shijubo N, Ohmichi M et al (2001) IL12 and IL18 are increased and stimulated IFN-γ production in sarcoid lungs. J Immunol 166:642–649PubMed

16.

Belkhou A, Younsi R, El Bouchti I, El Hassani S (2008) Rituximab as a treatment alternative in sarcoidosis. Joint Bone Spine 75:511–512PubMedCrossRef

17.

Ramos-Casals M, Brito-Zeron P, Munoz S, Soto MJ (2008) A systemic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine 87:345–364PubMedCrossRef

18.

Mikuniya T, Nagai S, Takeuki N et al (2000) Significance of the IL1-receptor antagonist/IL1-beta ratio as a prognostic factor in patients with pulmonary sarcoidosis. Respiration 67:389–396PubMedCrossRef

19.

Scallon BJ, More MA, Trinh H (1995) Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 7:251–259PubMedCrossRef

20.

Baughman RP, Lower EE (2001) Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 18:70–74PubMed

21.

Doty JD, Mazur JE, Judson MA (2005) Treatment of sarcoidosis with infliximab. Chest 127:1064–1071PubMedCrossRef

22.

Baughman RP, Drent M, Kavuru MS et al (2006) Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 174:795–802PubMedCrossRef

23.

Saleh S, Ghodsian S, Yakimova V, Henderson J, Sharma OP (2006) Effectiveness of infliximab in treating selected patients with sarcoidosis. Respir Med 100:2053–2059PubMedCrossRef

24.

Meyerle JH, Shoor A (2003) The use of infliximab in cutaneous sarcoidosis. J Drugs Dermatol 2:413–414PubMed

25.

Baughman RP, Bradley DA, Lower EE (2005) Infliximab for ocular chronic inflammation. Int J Clin Pharmacol Ther 43:7–11PubMed

26.

Sollberger M, Fluri F, Baumann T (2004) Successful treatment of steroid-refractory neurosarcoidosis with infliximab. J Neurol 251:760–761PubMedCrossRef

27.

Kobylecki C, Shaunak S (2007) Refractory neurosarcoidosis responsive to infliximab. Practical Neurol 7:112–115

28.

Moravan M, Segal BM (2009) Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil. Neurology 72:337–340PubMedCrossRef

29.

Rossman M, Newman LS, Baughman RP et al (2006) A double-blind, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 23:201–208PubMed

30.

Judson MA, Baughman RP, Costabel U et al (2008) Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomized trial. Eur Respir J 31:1189–1196PubMedCrossRef

31.

Agarwal S, Bhagat S, Dasgupta B (2009) Sarcoid sacroiliitis: successful treatment with infliximab. Ann Rheum Dis 68(2):283CrossRef

32.

Sodhi M, Pearson K, White ES, Culver DA (2009) Infliximab therapy rescues cyclophosphamide failure in severe CNS sarcoidosis. Respir Med 103(2):268–273PubMedCrossRef

33.

Corbett J (2009) Treating CNS sarcoidosis with infliximab and MMF. Curr Neurosci Rep 9:339–340CrossRef

34.

Dhingra N, Morgan J, Dick AD (2009) Switching biological agents for uveitis. Eye 23:1868–1870PubMedCrossRef

35.

Thielen AM, Barde C, Saurat JH, Laffitte E (2009) Refractory chronic cutaneous sarcoidosis responsive to dose escalation of TNF alpha antagonists. Dermatology 219:59–62PubMedCrossRef

36.

Arnaud L, Sene D, Costedoat-Chalumeau N et al (2009) Disseminated cryptococcal infection and anti-TNFalpha treatment for refractory sarcoidosis: an expected association? J Rheumatol 36:462–463PubMedCrossRef

37.

Judson MA (2009) Allergic pulmonary aspergillosis and infliximab therapy for sarcoidosis: a potential mechanism related to T-helper cytokine balance. Chest 136:526–535PubMedCrossRef

38.

Josse S, Klemmer N, Moreno-Swirc S et al (2009) Infliximab induced skin and pulmonary sarcoidosis in a rheumatoid arthritis patient. Joint Bone Spine 76(6):718–719PubMedCrossRef

39.

Massara A, Cavazzini L, La Corte R, Trotta F (2010) Sarcoidosis appearing during Anti-tumor necrosis factor alpha therapy: a new “Class Effect” paradoxical phenomenon. Two case reports and literature review. Semin Arthritis Rheum 39:313–319PubMedCrossRef

40.

Daien CI, Monnier A, Claudepierre P et al (2009) Sarcoidosis-like granulomatosis in patients treated with TNF alpha blockers: 10 cases. Rheumatology 48:883–886PubMedCrossRef

41.

Baughman RP, Shipley R, Desai S et al (2009) Changes in chest roentgenogram of sarcoidosis patients during a clinical trial of infliximab therapy: comparison of different methods of evaluation. Chest 136:526–535PubMedCrossRef

42.

Stagaki E, Mountford WK, Lackland DT, Judson MA (2009) The treatment of lupus pernio: results of 116 treatment courses in 54 patients. Chest 135(2):468–476PubMedCrossRef

43.

Moreland LW, Schiff MH, Baumgartner SW (1999) Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 130:478–486PubMed

44.

Khanna D, Liebling M, Louise JS (2003) Etanercept ameliorates sarcoidosis arthritis and skin disease. J Rheumatol 30:1864–1867PubMed

45.

Utz JP, Limper AH, Kalra S et al (2003) Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 124:177–185PubMedCrossRef

46.

Baughman RP, Lower EE, Bradley DA, Raymond LA, Kaufman A (2005) Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest 128:1062–1067PubMedCrossRef

47.

Hobbs K (2005) Chronic sarcoid arthritis treated with intraarticular etanercept. Arthritis Rheum 52:987–988PubMedCrossRef

48.

Sweiss NJ, Welsch MJ, Curran JJ, Ellman MH (2005) Tumor necrosis factor inhibition as a novel treatment for refractory sarcoidosis. Arthritis Rheum 53:788–791PubMedCrossRef

49.

Suzuki J, Goto H (2009) Uveitis associated with sarcoidosis exacerbated by etanercept therapy. Jpn J Ophthalmol 53(4):439–440PubMedCrossRef

50.

Thielen AM, Barde C, Saurat JH, Laffitte E (2009) Refractory chronic cutaneous sarcoidosis responsive to dose escalation of TNF-alpha antagonists. Dermatology 219(1):59–62PubMedCrossRef

51.

Skoie IM, Wildhagen K, Omdal R (2010) Development of sarcoidosis following etanercept treatment: a report of 3 cases. Rheumatol Int (in press)

52.

Takatori S, Kamata Y, Murosaki T et al (2010) Abrupt development of sarcoidosis with a prodromal increase in plasma osteopontin in a patient with rheumatoid arthritis during treatment with etanercept. J Rheumatol 37(1):210–211PubMedCrossRef

53.

Samimi M, Lorette G, Machet L et al (2009) Facial granulomatous nodules during etanercept treatment for psoriasis. Int J Dermatol 48(9):1025–1027PubMedCrossRef

54.

Baker DE (2004) Adalimumab: human recombinant immunoglobulin G1 anti-tumor necrosis factor monoclonal antibody. Rev Gastroenterol Disord 4:196–210PubMed

55.

Philips MA, Lynch J, Azmi FH (2005) Ulcerative cutaneous sarcoidosis responding to adalimumab. Acad Dermatol 53:917CrossRef

56.

Hefferman MP, Smith DI (2006) Adalimumab for treatment of cutaneous sarcoidosis. Arch Dermatol 142:17–19CrossRef

57.

Callejas-Rubio JL, Ortego-Centeno N, Lopez-Perez L, Benticuaga MN (2006) Treatment of therapy-resistant sarcoidosis with adalimumab. Clin Rheumatol 25:596–597

58.

Patel SR (2009) Systemic sarcoidosis with bone marrow involvement responding to therapy with adalimumab: a case report. J Med Case Reports 3:8573PubMedCrossRef

59.

Cufí-Benet M, Sabadell C, Codina O (2010) Adalimumab in the treatment of parotid sarcoidosis. Arch Bronconeumol 46:49–50PubMedCrossRef

60.

Marnane M, Lynch T, Scott J et al (2009) Steroid-unresponsive neurosarcoidosis successfully treated with adalimumab. J Neurol 256(1):139–140PubMedCrossRef

61.

Metyas SK, Tadros RM, Arkfeld DG (2009) Adalimumab-induced noncaseating granuloma in the bone marrow of a patient being treated for rheumatoid arthritis. Rheumatol Int 29(4):437–439PubMedCrossRef

62.

Dhaille F, Viseux V, Caudron A et al (2010) Cutaneous sarcoidosis occurring during anti-TNFalpha treatment: reporting of two cases. Dermatology 220:234–237PubMedCrossRef

63.

Gifre L, Ruiz-Esquide V, Xaubet A et al (2011) Lung sarcoidosis induced by TNF antagonists in rheumatoid arthritis: a case presentation and a literature review. Arch Bronchoneumol 47:208–212

64.

Antoniu SA (2010) Targeting the TNF alpha pathway in sarcoidosis. Expert Opin Ther Targets 14:21–29PubMedCrossRef

65.

Schafer P, Parton A, Gandhi A et al (2010) Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol 159(4):842–855PubMedCrossRef

66.

Statkute L, Ruderman EM (2010) Novel TNF antagonists for the treatment of rheumatoid arthritis. Expert Opin Investig Drugs 19:105–115PubMedCrossRef

67.

Soriano ER, Rosa J (2009) Update on the treatment of peripheral arthritis in psoriatic arthritis. Curr Rheumatol Rep 11:270–277PubMedCrossRef

68.

Antoniu SA (2009) Golimumab for severe asthma. Expert Opin Investig Drugs 18:1421–1423PubMedCrossRef

69.

Tavares JL, Wangoo A, Dilworth P et al (1997) Thalidomide reduces tumour necrosis factor-alpha production by human alveolar macrophages. Respir Med 91:31–39PubMedCrossRef

70.

Ye Q, Chen B, Tong Z et al (2006) Thalidomide reduces IL-18, IL-8 and TNF-alpha release from alveolar macrophages in interstitial lung disease. Eur Respir J 26:824–831CrossRef

71.

Carlesimo M, Giustini S, Rossi A, Bonaccorsi P, Calvieri S (1995) Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol 32:866–869PubMedCrossRef

72.

Baughman RP, Judson MA, Teirstein AS, Moller DR, Lower EE (2002) Thalidomide for chronic sarcoidosis. Chest 122:227–232PubMedCrossRef

73.

Judson MA, Silvestri J, Hartung C, Byars T, Cox CE (2006) The effect of thalidomide on corticosteroid-dependent pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 23:51–57PubMed

74.

Marriott JB, Dredge K, Dalgreish AG (2003) Thalidomide derived immunomodulatory drugs (ImiDs) as potential therapeutic agents. Curr Drug Targets Immune Endocr Metabol Disord 3:181–186PubMedCrossRef

75.

Yasui K, Yashiro M, Tsuge M et al (2010) Thalidomide dramatically improves the symptoms of early-onset sarcoidosis/Blau syndrome: its possible action and mechanism. Arthritis and Rheum 62:250–257CrossRef

76.

Marques LJ, Zheng L, Poulakis N, Guzman J, Costabel U (1999) Pentoxifylline inhibits TNFα production from alveolar macrophages. Am J Respir Crit Care Med 159:508–511PubMed

77.

Tong Z, Dai H, Chen B, Abdoh Z, Guzman J, Costabel U (2004) Inhibition of cytokine release from alveolar macrophages in pulmonary sarcoidosis by pentoxifylline: comparison with dexamethasone. Chest 124:1526–1532CrossRef

78.

Zabel P, Entzian P, Dalhoff K, Schlaak M (1997) Pentoxifylline in treatment of sarcoidosis. Am J Crit Care Med 155:1665–1669

79.

Manganiello VC, Park MK, Stylianou M et al (2005) A randomized trial of pentoxifylline in pulmonary sarcoidosis. American Thoracic Society 2005 international conference, 20–25 May. San Diego, California, p A14

80.

Elliott M, Benson J, Blank M et al (2009) Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases. Ann N Y Acad Sci 1182:97–110PubMedCrossRef

81.

Griffiths CE, Strober BE, van de Kerkhof P et al (2010) Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 362:118–128PubMedCrossRef

82.

Shear NH, Prinz J, Papp K, Langley RG, Gulliver WP (2008) Targeting the interleukin-12/23 cytokine family in the treatment of psoriatic disease. J Cutan Med Surg 12:s1–s10PubMed

83.

St. Clair EW (2009) Novel targeted therapies for autoimmunity. Curr Opin Immunol 21:648–657PubMedCrossRef

84.

Belkhou A, Younsi R, El Bouchti I et al (2008) Rituximab as a treatment alternative in sarcoidosis. Joint Bone Spin 75:511–512CrossRef

85.

Gottemberg J, Guillevin L, Lambotte O et al (2005) Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 64:913–920CrossRef

86.

Dasilva V, Breuil V, Chevallier P et al (2010) Relapse of severe sarcoidosis with an uncommon peritoneal location after TNF alpha blockade. Efficacy of rituximab, report of a single case. Joint Bone Spine 77:82PubMedCrossRef

87.

Régent A, Mouthon L (2009) Anti-TNFalpha therapy in systemic autoimmune and/or inflammatory diseases. Presse Med 38(5):761–773PubMedCrossRef

88.

Baughman RP, Lower EE, Drent M (2008) Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them. Sarcoidosis Vasc Diffuse Lung Dis 25(2):76–89PubMed

Titel: Cytokine modulators in the treatment of sarcoidosis
verfasst von: E. Bargagli
C. Olivieri
P. Rottoli
Publikationsdatum: 01.12.2011
Verlag: Springer-Verlag
Erschienen in: Rheumatology International / Ausgabe 12/2011
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-011-1969-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

CKD bei Diabetes: Neuheiten und Zukunftsaussichten

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Jeder Mensch mit Diabetes muss auf eine chronische Nierenerkrankung gescreent werden – diese neue Empfehlung spricht die KDIGO aus. Die Therapie erfolgt individuell und je nach Szenario mit verschiedenen Substanzklassen. Künftig kommt wahrscheinlich, neben RAS-Hemmung, SGLT2-Inhibition und nsMRA, eine vierte Therapiesäule hinzu.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2011

Circulating endothelial microparticles in children with Henoch–Schönlein purpura; preliminary results

Evaluation of osteoarthritis induced by treadmill-running exercise using the modified Mankin and the new OARSI assessment system

Anti-cyclic citrullinated peptide and rheumatoid factor in HIV positive patients

Clinical efficacy of the smartplug™ in the treatment of primary Sjogren’s syndrome with keratoconjunctivitis SICCA: one-year follow-up study

Late onset lupus nephritis: analysis of clinical manifestations and renal pathological features in Chinese patients